1. Home
  2. DMLP vs AVLN Comparison

DMLP vs AVLN Comparison

Compare DMLP & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DMLP

Dorchester Minerals L.P.

HOLD

Current Price

$26.49

Market Cap

1.3B

Sector

Energy

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$34.62

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DMLP
AVLN
Founded
2003
N/A
Country
United States
United States
Employees
26
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2002
2026

Fundamental Metrics

Financial Performance
Metric
DMLP
AVLN
Price
$26.49
$34.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
273.8K
183.9K
Earning Date
05-07-2026
N/A
Dividend Yield
9.98%
N/A
EPS Growth
N/A
N/A
EPS
1.20
N/A
Revenue
$152,832,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.85
$24.90
52 Week High
$28.95
$34.15

Technical Indicators

Market Signals
Indicator
DMLP
AVLN
Relative Strength Index (RSI) 50.07 64.86
Support Level $26.43 $27.11
Resistance Level $28.72 N/A
Average True Range (ATR) 0.60 1.90
MACD -0.11 0.78
Stochastic Oscillator 45.73 85.46

Price Performance

Historical Comparison
DMLP
AVLN

About DMLP Dorchester Minerals L.P.

Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonuses, and others.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: